Survivorship clinic franchise — the honest answers.

Adult and AYA (adolescent and young adult) survivors of solid tumors, hematologic malignancies, and HSCT recipients who are ≥ 2 years off active treatment or transitioning from oncology follow-up. Care is aligned to NCCN Survivorship, ASCO, and COG-LTFU 6.0 guidelines.

No. The franchise is a survivorship and long-term follow-up practice. Active treatment stays with the referring oncology center. We own the post-treatment surveillance, late-effects screening, cardio-oncology and endocrine-late-effects coordination, psychosocial care, and transition-of-care handoffs.

Cardiotoxicity (anthracycline / HER2 / radiation), secondary malignancies, endocrine dysfunction (thyroid, gonadal, growth), pulmonary fibrosis, nephrotoxicity, neurocognitive change, fertility, bone health, chronic pain, lymphedema, and psychosocial distress — mapped to exposure history via a structured treatment summary.

Two to three provider chairs open 8–5, five days a week. New survivorship consults (60 min) build the treatment summary and care plan. Annual surveillance visits (30–45 min) and interval follow-ups (20 min). In-clinic ECG, echo scheduling, DEXA orders, and labs (CBC, CMP, TSH, lipid panel, HbA1c). Care plans sent to PCP and referring oncologist the same day.

A preconfigured tenant of Life Spark Spark OS: NCCN/ASCO/COG-LTFU protocol library, treatment-summary builder, cardio-oncology and vaccine-timing calculators, patient-facing survivorship portal, and FHIR-based data exchange with referring centers. Setup, training, and seat licensing bundled into the monthly platform fee.

Yes for interval follow-ups, symptom check-ins, and psychosocial visits, subject to each state's telemedicine rules. The initial survivorship consult and any exam-dependent surveillance visit is in person.

One MD or DO medical director with oncology, hem-onc, or internal-medicine survivorship experience (0.2–0.4 FTE), one NP or PA as full-time survivorship clinician, one RN care coordinator, one social worker or psycho-oncology navigator (0.5 FTE), one medical assistant, and one front-desk / patient navigator. Total ≈ 4.5 FTE at open, scaling to 7 FTE at full panel.

Preferred but not required. Acceptable backgrounds: medical/hematologic/pediatric oncology, internal medicine with survivorship fellowship, or family medicine with substantial survivorship experience. The MD provides clinical oversight, tumor-board attendance, and cardio-oncology consult access; supervision structure follows state scope-of-practice rules.

Board certification, active state license, and completion of the 24-hour Life Spark Survivorship Curriculum (treatment summaries, NCCN/COG-LTFU surveillance, cardio-oncology basics, fertility and psychosocial screening) within the first 90 days. Ongoing 12 hours of survivorship CE per year.

Yes. This program is a franchise offering as defined by 16 CFR Part 436: trademark license, significant operational control, and required payment. A Franchise Disclosure Document (FDD) is issued to every prospect at least 14 days before signing, and the franchise is registered in the 14 registration states.

The franchisee is the covered entity for its patients. Life Spark signs a Business Associate Agreement (BAA) as the platform vendor. Franchisee is responsible for its own workforce HIPAA training, breach response, and OCR reporting; the operating manual provides templates and an annual audit checklist.

In CPOM states (CA, TX, NY and ~30 others) clinical services are delivered through a physician-owned professional corporation (PC) with a management services agreement (MSA) between the PC and the franchisee's management company. Our legal partners provide a standard PC/MSA template as part of onboarding. Franchisee retains business ownership; the PC retains all clinical decision-making.

Via FHIR R4 endpoints (Epic, Oracle Health/Cerner, Athena, eCW) and CDA documents for legacy systems. Every exchange is logged in the PHI access log, patient-consented, and BAA-covered. Care plans and surveillance updates are pushed to the referring center after each visit.

Yes. Franchisees receive a protected radius (typically 3–5 miles urban, 10 miles suburban, negotiable rural) plus a 2-year post-termination non-compete inside that radius. Full terms are in Item 12 of the FDD.

Estimated $310,000–$540,000 all-in for a single unit, per Item 7 of the FDD: $40,000 initial franchise fee, $130–$240K buildout (1,800–2,600 sq ft), $45–$85K equipment (exam-room fit-out, ECG, InBody, phlebotomy station), $25K working capital reserve at open, and $70–$150K first-6-month operating float. Numbers vary by market — see the FDD for the current range.

6% royalty on gross clinical revenue, plus 2% brand-fund contribution. Royalties billed monthly on the 5th. The brand fund pays for national SEO, survivor education content, and clinical-guideline updates; it does not fund local marketing.

Blended mix: (1) E&M and preventive-medicine CPT codes billed to commercial and Medicare payers, (2) chronic care management (99490, 99487) and principal care management codes for high-risk survivors, (3) transitional care management after treatment completion, (4) employer contracts and self-pay memberships for AYA and executive-health survivors, and (5) grant-funded research participation. Coding playbook shipped with the operating manual.

Illustrative model (not a guarantee — see Item 19 FPRs): 2,200 active survivors, $2.1–$2.8M gross revenue, 34–42% clinic-level EBITDA margin, payback on initial investment in 26–34 months. Actual results depend heavily on payer mix, referring-center relationships, and local staffing costs.